Trial Profile

Phase I/IIa First in human study of GB-401 for patients with primary open angle glaucoma

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GB 401 (Primary)
Indications Open-angle glaucoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors CalciMedica; GrayBug inc.

Most Recent Events

20 Mar 2023 According to a CalciMedica media release, GrayBug has merger with CalciMedica and the combined company is named as CalciMedica.
30 Mar 2022 According to a GrayBug inc. media release, the company expect to initiate this trial in the first quarter of 2023, with safety and efficacy data expected to be available in the second quarter of 2023.
10 Mar 2022 According to a GrayBug inc. media release, the company expects to commence this study in the first half 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com